A capture immunoglobulin M (IgM) enzyme immunoassay was developed to diagnose La Crosse virus infections by the detection of specific IgM in acutephase serum specimens. IgM was detected by the capture IgM system in the serum of 24 of 29 (83%) of the patients studied. In comparison, IgM was detected in 19 of 29 (66%) of the patients by an indirect immunofluorescence technique. Specific IgM was detected in 83% (20 of 24) of patient serum specimens by day 3 after the onset of clinical symptoms.
